Kyle Wathen

Vice President, Scientific Strategy and Innovation

Kyle brings experience from a diverse background in academia, consulting, and the life sciences industry to his role at Cytel. Working on the development and application of novel Bayesian methodology for adaptive clinical trial designs, he is involved in each step of developing new adaptive clinical trial designs, starting from initial concept development through software development/trial simulation and completing with trial conduct and data collection.

Kyle has over 25 years of experience in the design of innovative clinical trials such as ​​Bayesian approaches, ​​platform trials and other ​​adaptive approaches. He has been involved in many innovative clinical trials, especially platform trials, in various disease areas including ​oncology, neuroscience, infectious diseases, cardiovascular and inflammation. Additionally, he has released several software packages including OCTOPUS, an R package for simulation of platform trials.

Kyle received his M.S. in statistics from Texas A&M University and M.S. and Ph.D. in Biostatistics from the University of Texas: Graduate School of Biomedical Sciences.